Elizna Van Zyl is a pharmacist who is specialized in Critical Care in Palo Alto, California. Patients can reach her at 500 Pasteur Dr, Palo Alto or contact her on 650-723-4000. Active license number of Elizna Van Zyl is 71121 for Critical Care in California. Elizna Van Zyl is a licensed pharmacist who has demonstrated specialized knowledge and skill in the delivery of patient care services by pharmacists, as integral members of interprofessional teams, working to ensure the safe and effective use of medications in critically ill patients.
Complete Profile:
Elizna Van Zyl speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Elizna Van Zyl
Specialization:
Critical Care
Credentials:
PHARMD
Gender:
Female
Location:
500 Pasteur Dr, Palo Alto, California, 94304-1048
Phone:
650-723-4000
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Elizna Van Zyl are as mentioned below.
NPI Number:
1215817606
NPI Enumeration Date:
05 Sep, 2025
NPI Last Update On:
05 Sep, 2025
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Elizna Van Zyl are as mentioned below.
Specialization
License Number
State
Status
Critical Care
71121
California
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1432 Crespi Dr, Pacifica, California
Zip:
94044-3606
Phone Number:
--
Fax Number:
--
Patients can reach Elizna Van Zyl at 500 Pasteur Dr, Palo Alto, California or can call on phone at 650-723-4000.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.